Literature DB >> 2878071

Receptor-mediated model relating anticonvulsant effect to brain levels of camazepam in the presence of its active metabolites.

A Morino, H Sasaki, H Mukai, M Sugiyama.   

Abstract

In a displacement test using 3H-diazepam as a radioligand, the in vitro affinities of metabolites of camazepam (CZ) for the benzodiazepine receptors were 1-50 times more potent than that of CZ. In contrast, only three metabolites (temazepam, oxazepam, and hydroxy CZ), as well as CZ itself, exhibited an in vivo affinity parallel to their ability to protect against pentylenetetrazole--induced clonic convulsion in rats. In addition, CZ and these active metabolites displaced the radioligand from their receptor sites in a concentration-dependent saturable manner, indicating the competitive bimolecular interaction of these molecules with their receptors. The percent anticonvulsant effect was a nonlinear, single-valued function of the in vivo percent displacement of specific 3H-diazepam binding, independent of these displacers after i.v. dosing; this relationship could be approximated by the Hill equation. On the basis of these findings, a receptor-mediated model, including the Langmuir equation to describe the receptor binding-brain concentration relationship and the Hill equation to accommodate the anticonvulsant effect-receptor binding relationship, was constructed. This model was found to adequately relate the time course values of anticonvulsant effect and of brain levels of CZ and its active metabolites after oral administration. These results demonstrate that CZ and its active metabolites exert anticonvulsant effect by competitive binding to the benzodiazepine receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878071     DOI: 10.1007/bf01106709

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  16 in total

1.  Evidence for a late evolutionary appearance of brain-specific benzodiazepine receptors: an investigation of 18 vertebrate and 5 invertebrate species.

Authors:  M Nielsen; C Braestrup; R F Squires
Journal:  Brain Res       Date:  1978-02-10       Impact factor: 3.252

2.  Benzodiazepine receptors: labeling in intact animals with [3H] flunitrazepam.

Authors:  R S Chang; S H Snyder
Journal:  Eur J Pharmacol       Date:  1978-03-15       Impact factor: 4.432

3.  Benzodiazepines: relationship between pharmacological activity in the rat and in vivo receptor binding.

Authors:  T Mennini; S Cotecchia; S Caccia; S Garattini
Journal:  Pharmacol Biochem Behav       Date:  1982-04       Impact factor: 3.533

4.  Correlation between benzodiazepine receptor occupation and anticonvulsant effects of diazepam.

Authors:  S M Paul; P J Syapin; B A Paugh; V Moncada; P Skolnick
Journal:  Nature       Date:  1979-10-25       Impact factor: 49.962

5.  Relation between time courses of pharmacological effects and of plasma levels of camazepam and its active metabolites in rats.

Authors:  A Morino; M Sugiyama
Journal:  J Pharmacobiodyn       Date:  1985-08

6.  Species differences in the disposition and metabolism of camazepam.

Authors:  A Morino; A Nakamura; K Nakanishi; N Tatewaki; M Sugiyama
Journal:  Xenobiotica       Date:  1985-12       Impact factor: 1.908

7.  Structure-affinity relationships between several new benzodiazepine derivatives and 3H-diazepam receptor sites.

Authors:  T Shibuya; R Field; Y Watanabe; K Sato; B Salafsky
Journal:  Jpn J Pharmacol       Date:  1984-04

8.  Kinetics of receptor occupation and anticonvulsive effects of diazepam in rats.

Authors:  Y Igari; Y Sugiyama; Y Sawada; T Iga; M Hanano
Journal:  Drug Metab Dispos       Date:  1985 Jan-Feb       Impact factor: 3.922

9.  The margin of safety of neuromuscular transmission.

Authors:  W D Paton; D R Waud
Journal:  J Physiol       Date:  1967-07       Impact factor: 5.182

10.  Species differences in clobazam metabolism and antileptazol effect.

Authors:  S Caccia; G Guiso; R Samanin; S Garattini
Journal:  J Pharm Pharmacol       Date:  1980-02       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.